ProMIS Neurosciences’ Neil Cashman to Speak at Protein Misfolding Drug Discovery Conference


ProMIS’ proprietary drug discovery and development platform highlighted forability to create novel antibodies, diagnostics and vaccine candidates for neurodegenerative diseases

TORONTO and CAMBRIDGE, Mass., Oct. 13, 2020 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced today that co-founder and Chief Scientific Officer Dr. Neil Cashman will be a member of the Speaking Faculty at the inaugural Protein Misfolding Drug Discovery Summit on October 28-29, 2020. Dr. Cashman joins speaking faculty from AbbVie, Neurimmune, Cambridge University Centre for Misfolding Diseases & Wren Therapeutics, Northwestern University, Prothena, Treventis and Yumanity to discuss the accelerated development of therapies for unmet neurodegenerative, metabolic and ophthalmic diseases as well as cancer.

Proteins that misfold and aggregate to form toxic oligomers in the central nervous system are considered a root cause of neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). These diseases lack effective therapies in large part because classical drug discovery and development approaches cannot selectively target the toxic oligomer with adequate precision. At this inaugural conference, intended to help shift this drug design and discovery paradigm, Dr. Cashman will highlight the unique ability of ProMIS’ proprietary drug discovery and development platform to address this enormous unmet need in his presentation, “Precision immunotherapies for protein misfolding diseases: the ProMIS platform.”

The ProMIS platform relies on a proprietary blend of physics, biology and supercomputing to rapidly and cost-effectively identify unique binding sites, called disease-specific epitopes (DSEs), on complex protein structures. ProMIS uses these DSEs to create peptide antigens, which are novel drug development tools that precisely mirror the sequence and shape (conformation) of these DSEs. This unique process enables the creation of antibody and vaccine candidates and potential diagnostics that are selective for the toxic form of proteins responsible for disease. Presently, the ProMIS portfolio in neurodegenerative diseases includes antibody therapeutic candidates for AD, PD and ALS, in addition to the recently announced development of a multivalent vaccine for AD.

“Protein misfolding is a root cause of multiple neurodegenerative diseases, as well as other disease states such as certain cancers,” said Dr. Neil Cashman. “Based on our unique technology platform we have created therapeutic antibody and vaccine candidates that are highly specific for the toxic form of misfolded proteins and can add to emerging capabilities in the measurement of blood-based biomarkers of neurodegenerative diseases, potentially leading to the ability to diagnose, treat and eventually prevent Alzheimer’s and other neurodegenerative diseases. By sharing our experiences with the larger community focused on protein misfolding diseases, we hope to help impact the broad spectrum of diseases with high unmet need for which protein abnormalities are a root cause.”

Protein Misfolding Drug Discovery 2020 will occur virtually on October 28-29, 2020. Participants may register online.

About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company whose unique core technology is the ability to rationally predict the site and shape (conformation) of novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of proteins. In neurodegenerative diseases, such as Alzheimer’s, ALS and Parkinson’s disease, the DSEs are misfolded regions on toxic forms of otherwise normal proteins. In the infectious disease setting, these DSEs represent peptide antigens that can be used as an essential component to create accurate and sensitive serological assays to detect the presence of antibodies that arise in response to a specific infection, such as COVID-19. ProMIS proprietary peptide antigens can also be used to create potential therapeutic antibodies, as well as serve as the basis for development of vaccines. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.

Visit us at, follow us on Twitter and LinkedIn. To learn more about protein misfolding diseases, listen to Episode 15 of the Saving Minds podcast at iTunes or Spotify.

For media inquiries, please contact:
Shanti Skiffington
Tel. 617 921-0808

For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
Tel. 617 901-0785

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

About GlobeNewswire

One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Norsk Hydro: PÅMINNELSE - Presentasjon av Hydros resultat for tredje kvartal 202021.10.2020 16:30:00 CESTPressemelding

Hydros resultat for tredje kvartal 2020 blir offentliggjort fredag 23. oktober 2020 kl. 07.00 (norsk tid). Kvartalsrapporten og presentasjonsmaterialet blir samtidig gjort tilgjengelig på Konsernsjef Hilde Merete Aasheim og konserndirektør for økonomi og finans Pål Kildemo vil presentere resultatet på engelsk samme dag kl. 08.30 (norsk tid) via audio webcast og telefonkonferanse. Pga. Covid-19-situasjonen vil det ikke bli pressekonferanse ved vårt hovedkontor. Presentasjonen kan følges via audio webcast. Det vil være mulig å stille spørsmål rett etter presentasjonen. For å stille spørsmål må du være koblet på telefonkonferansen før presentasjonen er ferdig. Se detaljer nedenfor (det vil ikke være mulig å stille spørsmål via audio webcast). Du melder deg på telefonkonferansen ved å klikke på lenken “Click to Join“ 5-10 minutter før start. Du må oppgi telefonnummer og registreringsdetaljer. Konferansesystemet vil ringe tilbake på det oppgitte telefonnummeret og koble deg t

Norsk Hydro: REMINDER - Hydro’s third quarter results 202021.10.2020 16:30:00 CESTPress release

Hydro's third quarter results 2020 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC), on Friday October 23, 2020. The quarterly report and presentation slides will be available on at the same time. President & CEO Hilde Merete Aasheim and EVP & CFO Pål Kildemo will host an audio webcast and a conference call, in English, at 08:30 CEST the same day. Due to the Covid-19 situation, there will be no analyst and press conference at our corporate headquarters. In order to listen to the presentation, please join the audio webcast. There will be a Q&A session directly after the presentation. If you would like to ask questions, you need to join the conference call before end of the presentation. See details below (it will not be possible to ask questions on the audio webcast). To join the conference call, please use the “Click to Join” link below 5-10 minutes prior to start time. You will be asked to enter your phone number and registration details. The Event Confer


SEK TENDER OPERATION ANNOUNCEMENT FOR ONWARD LENDING 2020-10-23 Transaction type:SEK CreditTender date:2020-10-23Time for submission of bids:10.30-11.00 (CEST)Payment date:2020-10-27Final repayment date2024-10-28Offered volume:50 billion SEKMinimum bid amount:10 million SEKMaximum bid amount:12.5 billion SEKMaximum number of bids from each participant: 1Interest rate:0.00 %Additional interest rate:0.10 per cent ALL APPROVED COUNTERPARTIES ARE INVITED TO SUBMIT VOLUME BIDS TO THE RIKSBANK (46-8-6966970) BY 11.00 ON OCTOBER 23 2020, AT THE LATEST. CONFIRMATION ON E-MAIL: Result of the auction will be published at 11.30 (CEST) on Tender date. Complete terms and conditions can be retrieved at

Enento Group’s financial information 202121.10.2020 14:30:00 CESTPress release

ENENTO GROUP PLC, STOCK EXCHANGE RELEASE 21 OCTOBER 2020 AT 3.30 P.M. EEST Enento Group’s financial information 2021 Enento Group Plc will publish its Financial Statements Bulletin for 2020 on Friday, 12 February 2021. The Annual Report and Financial Statements 2020 will be published in week 10 at Enento Group’s Annual General Meeting is planned to be held on Monday, 29 March 2021. The notice to convene the Annual General Meeting will be given later on by the Board of Directors. Enento Group’s financial reporting in 2021 Financial Statements Bulletin for 2020 on Friday, 12 February 2021Interim Report for January – March 2021 on Thursday, 29 April 2021Half Year Financial Report for January – June 2021 on Wednesday, 21 July 2021Interim Report for January – September 2021 on Friday, 29 October 2021 All financial reports are published in English and Finnish and they are also available at after the publication. ENENTO GROUP PLC For

ArcAroma AB: 201021 ArcAromas dotterbolag tecknar nytt utvärderingsavtal om oliveCEPT® i Kina21.10.2020 13:30:00 CESTPressemelding

Pressmeddelande 2020-10-21 ArcAromas dotterbolag ArcAroma Shanghai Ltd har tecknat ett utvärderingsavtal med en modern olivoljeproducent i Zhonze, Kina. Utvärderingen kommer genomföras vid kundens produktionsanläggning från oktober till december 2020. Kunden kommer enligt avtalet att köpa en oliveCEPT®-enhet om de överenskomna målen uppnås under utvärderingsperioden. Enligt överenskommelsen kommer en oliveCEPT®-enhet att placeras före malaxering i kundens produktionsprocess, vilket förväntas ge fem till tio procent i ökad extraktion av Extra Virgion Olivolja (EVOO). Kunden kommer att optimera processtiden under produktionssäsongen med målsättningen att korta ned malaxeringstiden mot 10 till 15 minuter, vilket i så fall innebär en processeffektivisering på uppåt 30 minuter. Om målsättningarna uppnås under produktionsperioden så kommer utvärderingen att utmynna i ett försäljningsavtal uppgående till 150 000 EUR under första eller andra kvartalet 2021. ”Kina är en växande EVOO-marknad med